Novel targeted therapy for acute myeloid leukemia with a dual FLT3 and JAK2 inhibitor

Acta Pharmacologica Sinica

Volumn 33, Issue 2, 2012, Pages 212-213

  Lou, Yin Jun ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CD135 ANTIGEN; JANUS KINASE 2 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PACRITINIB; SB 1518; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL LINE; CELL PROLIFERATION; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; FLOW CYTOMETRY; GENE MUTATION; IC 50; IN VIVO STUDY; MOLECULARLY TARGETED THERAPY; MYELOFIBROSIS; PHASE 2 CLINICAL TRIAL (TOPIC); TUMOR REGRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; BRIDGED COMPOUNDS; FMS-LIKE TYROSINE KINASE 3; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOID, ACUTE; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 84856840002     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2011.206     Document Type: Article

References (7)

1. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008; 111: 2505-15.
2. Fathi A, Levis M. FLT3 inhibitors: a story of the old and the new. Curr Opin Hematol 2011; 18: 71-6.
3. Stein BL, Crispino JD, Moliterno AR. Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms. Curr Opin Oncol 2011; 23: 609-16.
4. Hart S, Goh KC, Novotny-Diermayr V, Hu CY, Hentze H, Tan YC, et al. Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia. Blood Cancer J 2011; 1: e44.
5. Hart S, Goh KC, Novotny-Diermayr V, Tan YC, Madan B, Amalini C, et al. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia 2011; 25: 1751-9.
6. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361: 1058-66.
7. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profling. J Clin Oncol 2011; 29: 3085-96.